Maktaba

Item request has been placed!

Item request cannot be made.

Processing Request

Academic Journal

Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19.

Authors : Norton TD; Thakur M ...

Subjects: Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/pharmacokinetics ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/therapeutic use ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/adverse effects

Source: Journal of the Pediatric Infectious Diseases Society [J Pediatric Infect Dis Soc] 2024 Nov 27; Vol. 13 (11), pp. 589-593.Publisher: Oxford University Press Country of Publication: England NLM ID: 101586049 Publication Model: Print Cited Medium:

Record details

Read Online Read More Add to Saved list

Academic Journal

Investigation of plaque psoriasis relapse after secukinumab withdrawal in patients from two phase III studies.

Authors : Lebwohl M; Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Iversen L

Subjects: Psoriasis*/Psoriasis*/Psoriasis*/drug therapy ; Psoriasis*/Psoriasis*/Psoriasis*/pathology ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/therapeutic use

Source: Clinical and experimental dermatology [Clin Exp Dermatol] 2024 Jul 19; Vol. 49 (8), pp. 793-800.Publisher: Oxford University Press Country of Publication: England NLM ID: 7606847 Publication Model: Print Cited Medium:

Record details

Read Online Read More Add to Saved list

Academic Journal

Deep resolution of clinical, cellular and transcriptomic inflammatory markers of psoriasis over 52 weeks of interleukin-17A inhibition by secukinumab.

Authors : Tomalin LE; Department of Population Health Science and Policy, Department of Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Kolbinger F

Subjects: Psoriasis*/Psoriasis*/Psoriasis*/drug therapy ; Psoriasis*/Psoriasis*/Psoriasis*/genetics ; Psoriasis*/Psoriasis*/Psoriasis*/pathology

Source: Clinical and experimental dermatology [Clin Exp Dermatol] 2024 Jul 19; Vol. 49 (8), pp. 801-809.Publisher: Oxford University Press Country of Publication: England NLM ID: 7606847 Publication Model: Print Cited Medium:

Record details

Read Online Read More Add to Saved list

Editorial & Opinion

Secukinumab therapy for paediatric patients with various phenotypes of congenital ichthyosis.

Authors : Albela H; Department of Paediatrics, Sarawak General Hospital, Kuching, Malaysia.; Ting IPL

Subjects: Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/therapeutic use ; Phenotype*; Child

Source: Clinical and experimental dermatology [Clin Exp Dermatol] 2024 Jul 19; Vol. 49 (8), pp. 920-922.Publisher: Oxford University Press Country of Publication: England NLM ID: 7606847 Publication Model: Print Cited Medium:

Record details

Read Online Read More Add to Saved list

Academic Journal

Dupilumab-associated inflammatory arthritis: a literature review.

Authors : Napolitano M; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.; Ruggiero A

Subjects: Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/adverse effects ; Dermatitis, Atopic*; Humans

Source: Clinical and experimental dermatology [Clin Exp Dermatol] 2024 Mar 21; Vol. 49 (4), pp. 307-312.Publisher: Oxford University Press Country of Publication: England NLM ID: 7606847 Publication Model: Print Cited Medium:

Record details

Read Online Read More Add to Saved list

Editorial & Opinion

Sarilumab (interleukin-6 receptor monoclonal antibody) for the treatment of pemphigus vulgaris.

Authors : Andrew K; Dermatology Department, University Hospital Coventry, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.; Dhariwal SK

Subjects: Antibodies, Monoclonal*/Antibodies, Monoclonal*/Antibodies, Monoclonal*/therapeutic use ; Pemphigus*/Pemphigus*/Pemphigus*/drug therapy; Humans

Source: Clinical and experimental dermatology [Clin Exp Dermatol] 2023 Aug 25; Vol. 48 (9), pp. 1055-1056.Publisher: Oxford University Press Country of Publication: England NLM ID: 7606847 Publication Model: Print Cited Medium:

Record details

Read Online Read More Add to Saved list

Academic Journal

Medication use evaluation of tocilizumab implementation in COVID-19 treatment guidelines: A causal inference approach.

Authors : Goriacko P; Center for Pharmacotherapy Research and Quality, Department of Pharmacy, Montefiore Medical Center, Bronx, NY.; Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA.

Subjects: Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/therapeutic use ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/administration & dosage ; COVID-19 Drug Treatment*

Source: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists [Am J Health Syst Pharm] 2024 Oct 23; Vol. 81 (21), pp. Publisher: Oxford University Press Country of Publication: England NLM ID: 9503023 Publication Model: Print Cited Medium:

Record details

Read Online Read More Add to Saved list

Academic Journal

Efficacy and safety of bimekizumab in real-world psoriasis management: data from patients who are biologic-naive vs. biologic-experienced.

Authors : Megna M; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.; Ruggiero A

Subjects: Psoriasis*/Psoriasis*/Psoriasis*/drug therapy ; Severity of Illness Index* ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/therapeutic use

Source: Clinical and experimental dermatology [Clin Exp Dermatol] 2024 Sep 18; Vol. 49 (10), pp. 1186-1189.Publisher: Oxford University Press Country of Publication: England NLM ID: 7606847 Publication Model: Print Cited Medium:

Record details

Read Online Read More Add to Saved list

Academic Journal

Gut Microbial Species and Endotypes Associate with Remission in Ulcerative Colitis Patients Treated with Anti-TNF or Anti-integrin Therapy.

Authors : Tamburini FB; Human Pathobiology & OMNI Reverse Translation, Genentech, South San Francisco, CA, USA.; Tripathi A

Subjects: Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/therapeutic use ; Colitis, Ulcerative*/Colitis, Ulcerative*/Colitis, Ulcerative*/drug therapy ; Colitis, Ulcerative*/Colitis, Ulcerative*/Colitis, Ulcerative*/microbiology

Source: Journal of Crohn's & colitis [J Crohns Colitis] 2024 Nov 04; Vol. 18 (11), pp. 1819-1831.Publisher: Oxford University Press Country of Publication: England NLM ID: 101318676 Publication Model: Print Cited Medium:

Record details

Read Online Read More Add to Saved list

Academic Journal

Real-World Comparison of the Effectiveness between Ustekinumab and Vedolizumab in Patients with Ulcerative Colitis Exposed to at least One Anti-TNF Agent.

Authors : Fumery M; Gastroenterology Department, Amiens University Hospital, Université de Picardie Jules Verne, Unité Peritox, France.; Serrero M

Subjects: Colitis, Ulcerative*/Colitis, Ulcerative*/Colitis, Ulcerative*/drug therapy ; Ustekinumab*/Ustekinumab*/Ustekinumab*/therapeutic use ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/therapeutic use

Source: Journal of Crohn's & colitis [J Crohns Colitis] 2024 Oct 15; Vol. 18 (10), pp. 1615-1621.Publisher: Oxford University Press Country of Publication: England NLM ID: 101318676 Publication Model: Print Cited Medium:

Record details

Read Online Read More Add to Saved list

Search Results

Your Filters

Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19.

Investigation of plaque psoriasis relapse after secukinumab withdrawal in patients from two phase III studies.

Deep resolution of clinical, cellular and transcriptomic inflammatory markers of psoriasis over 52 weeks of interleukin-17A inhibition by secukinumab.

Secukinumab therapy for paediatric patients with various phenotypes of congenital ichthyosis.

Dupilumab-associated inflammatory arthritis: a literature review.

Sarilumab (interleukin-6 receptor monoclonal antibody) for the treatment of pemphigus vulgaris.

Medication use evaluation of tocilizumab implementation in COVID-19 treatment guidelines: A causal inference approach.

Efficacy and safety of bimekizumab in real-world psoriasis management: data from patients who are biologic-naive vs. biologic-experienced.

Gut Microbial Species and Endotypes Associate with Remission in Ulcerative Colitis Patients Treated with Anti-TNF or Anti-integrin Therapy.

Real-World Comparison of the Effectiveness between Ustekinumab and Vedolizumab in Patients with Ulcerative Colitis Exposed to at least One Anti-TNF Agent.

Contact

Follow us